

Journal-Publikationen 2010 - 08/2016

Greenberg PL, **Tuechler H**, Schanz J, et al. (2016): Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. Blood. August 2016. 10.1182/blood-2016-07-728766.

Kisser A, **Tüchler H**, Erdös J, Wild C. (2016): Factors influencing coverage decisions on medical devices: A retrospective analysis of 78 medical device appraisals for the Austrian hospital benefit catalogue 2008-2015. Health Policy. June 2016. 10.1016/j.healthpol.2016.06.007.

Pfeilstöcker M, **Tuechler H**, Sanz G, et al. (2016): Time-dependent changes in mortality and transformation risk in MDS. Blood. June 2016.

Bennett JM, **Tuechler H**, Aul C, Strupp C, Germing U (2016): Dysplastic erythroid precursors in the myelodysplastic syndromes and the acute myeloid leukemias: Is there biologic significance? (How should blasts be counted?). Leuk Res. 2016;47:63-69.

Braulke F, Platzbecker U, Mueller-Thomas C, Goetze K, Germing U, Bruemmendorf TH, Nolte F, Hofmann W-K, Giagounidis AAN, Luebbert M, Greenberg PL, Bennett JM, Sole F, Mallo M, Slovak ML, Ohyashiki K, Le Beau MM, **Tuechler H**, Pfeilstoecker M, Noesslinger T, Hildebrandt B, Shirneshan K, Aul C, Stauder R, Sperr WR, Valent P, Fonatsch C, Truemper L, Haase D, Schanz J (2015): Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+ISH: results from a German diagnostic study in comparison with an international control group. Haematologica 100, 205-213.

Della Porta MG, **Tuechler H**, Malcovati L, Schanz J, Sanz G, Garcia-Manero G, Sole F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Cermak J, Fonatsch C, Le Beau, M.M., Slovak, M.L., Krieger, O., Luebbert, M., Maciejewski, J., Magalhaes, S.M.M., Miyazaki Y, Pfeilstoecker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL, Cazzola M (2015): Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia.

Machherndl-Spandl S, Sega W, Boesmueller H, Germing U, Gruber C, Nachtkamp K, Reinecke P, Sperr WR, Wimazal F, Muellauer L, Sotlar K, Horny HP, **Tuechler H**, Valent P, Krieger O (2014): Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis. Ann. Hematol. 93, 57-64.

Schanz J, **Tuechler H**, Sole F, Mallo M, Luno E, Cervera J, Grau J, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstoecker M, Noesslinger T, Valent P, Giagounidis A, Aul C, Luebbert M, Stauder R, Krieger O, Beau MML, Bennett JM, Greenberg P, Germing U, Haase D (2013): Monosomal karyotype in MDS: explaining the poor prognosis? Leukemia 27, 1988-1995.

Greenberg PL, **Tuechler H**, Schanz J, Sanz G, Garcia-Manero G, Sole F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SMM, Miyazaki Y, Pfeilstoecker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D (2012): Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120, 2454-2465.

Schanz J, **Tuechler H**, Sole F, Mallo M, Luno E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstoecker M, Noesslinger T, Valent P, Giagounidis A, Aul C, Luebbert M, Stauder R, Krieger O, Garcia-Manero G, Faderl S, Pierce S, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D (2012): New comprehensive cytogenetic

scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. *J. Clin. Oncol.* 30, 820-829.

Pfeilstoecker M, **Tuechler H**, Schoenmetzler A, Noesslinger T, Pittermann E (2011): Time changes in predictive power of established and recently proposed clinical, cytogenetical and comorbidity scores for Myelodysplastic Syndromes. *Leuk Res.*

Piso B, **Tuechler H**, Gyimesi M, Kollmann I, Endel G, Wilbacher I, Kurz RW, Mueller R (2011): Ambulante kardiologische Phase-III-Rehabilitation - retrospektive Kohortenstudie zu einer Wiener Einrichtung[Outpatient cardiac phase III rehabilitation at a Viennese institution - retrospective cohort study]. *Wien Med Wochenschr* 161, 263-271.

Rosenmayr A, Pointner-Prager M, Mitterschiffthaler A, Bozic L, Pelzmann B, **Tuechler H**, Fae I, Fischer GF, Greinix HT, Peters C, Kalhs P, Krieger O, Linkesch W, Nachbaur D, Urban C, Posch U, Lanzer G, Gabriel C, Schennach H, Mayr W (2011): What are a patient's current chances of finding a matched unrelated donor? Twenty years' central search experience in a small country. *Bone Marrow Transplantation* 47, 172-180.

Rosenmayr A, Pointner-Prager M, Winkler M, Mitterschiffthaler A, Pelzmann B, Bozic L, Pichler S-K, **Tuechler H**, Fae I, Fischer G (2011): The Austrian Bone Marrow Donor Registry: Providing Patients in Austria with Unrelated Donors for Transplant - a Worldwide Cooperation. *Transfus Med Hemother* 38, 292-299.

Schanz J, Steidl C, Fonatsch C, Pfeilstoecker M, Noesslinger T, **Tuechler H**, Valent P, Hildebrandt B, Giagounidis A, Aul C, Luebbert M, Stauder R, Krieger O, Garcia-Manero G, Kantarjian H, Germing U, Haase D, Estey E (2011): Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. *J. Clin. Oncol.* 29, 1963-1970.

Noesslinger T, **Tuechler H**, Germing U, Sperr WR, Krieger O, Haase D, Luebbert M, Stauder R, Giagounidis A, Valent P, Pfeilstoecker M (2010): Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. *Ann. Oncol* 21, 120-125.